Switzerland· 66216003
Refixia 2000 IE, Pulver und Lösungsmittel zur Herstellung einer Injektionslösung
A coagulation factor ix product containing nonacogum beta pegolum, registered in Switzerland by Novo Nordisk Pharma AG and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 12 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Coagulation factor ix is registered in 12 of 19 countries.
Countries holding a registration under ATC B02BD04 (coagulation factor ix), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 8 of them publish a price we can compare per daily dose
Coagulation factor ix · ATC B02BD04
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
The record
At a glance
Swissmedic (Switzerland)- Active substance
- nonacogum beta pegolum
- Manufacturer
- Novo Nordisk Pharma AG
- Country
- Switzerland (CH)
- ATC code
- B02BD04
- ATC class
- Coagulation factor IX
- Defined daily dose
- 600 E, P
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin76806621600331 StkCHF 3691.05
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
3 interactions on record for coagulation factor ix.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Coagulation factor ix · interactions on record
3 records
- 2 severe
- 1 moderate
Most severe, free to view
- CarfilzomibL01XG02severe
- CarfilzomibL01XX45severe
- PegvaliaseA16AB19moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Coagulation factor ix in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwedenRefixia 1000 IE Pulver och vätska till injektionsvätska, lösningNovo Nordisk A/S
- CanadaREBINYNNOVO NORDISK CANADA INC
- United KingdomRefixia 1,000unit powder and solvent for solution for injection vialsNovo Nordisk Ltd
- IrelandRefixia 1 000 IU powder and solvent for solution for injectionNovo Nordisk A/S
- IcelandRefixiaNovo Nordisk A/S*
- NetherlandsRefixia 1000 IE, poeder en oplosmiddel voor oplossing voor injectieNovo Nordisk A.S.
- BelgiumRefixia 1000 IUNovo Nordisk
- CzechiaREFIXIANovo Nordisk A/S, Bagsvaerd
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Refixia
- Norway · Refixia
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bd741ffe-d119-43fe-8d00-e26922e7e9b2 GET /v1/drugs/bd741ffe-d119-43fe-8d00-e26922e7e9b2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "nonacogum beta pegolum 2000 UI",
"valid_from": "2024-12-01",
"limitations": null,
"galenic_form": "Trockensub 2000 IE c Solv",
"therapeutic_area": null,
"sl_inclusion_date": "2017-11-01",
"self_retention_pct": 10
}See everything about coagulation factor ix.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.